Klimek, LJutel, MAkdis, CBousquet, JAkdis, MBachert, CAgache, IAnsotegui, IBedbrook, ABosnic-Anticevich, SCanonica, GWChivato, TCruz, AACzarlewski, WDel Giacco, SDu, HFonseca, JAGao, YDHaahtela, THoffmann-Sommergruber, KIvancevich, JCKhaltaev, NKnol, EFKuna, PLarenas-Linnemann, DMelén, EMullol, JNaclerio, ROhta, KOkamoto, YO'Mahony, LOnorato, GLPapadopoulos, NGPawankar, RPfaar, OSamolinski, BSchwarze, JToppila-Salmi, SShamji, MHVentura, MTValiulis, AYorgancioglu, AMatricardi, PZuberbier, T2025-04-102025-04-100105-4538http://hdl.handle.net/20.500.14701/43288The current COVID-19 pandemic influences many aspects of personal and social interaction, including patient contacts with health care providers and the manner in which allergy care is provided and maintained. Allergen-specific immunotherapy (AIT) is one of the most important treatment options for IgE-mediated allergies and is based on inducing an appropriate immune response in the allergic patient. This manuscript outlines the EAACI recommendations regarding AIT during the COVID-19 pandemic and aims at supporting allergists and all physicians performing AIT in their current daily practice with clear recommendations on how to perform treatment during the pandemic and in SARS-CoV-2 infected patients.EnglishArticle1398-9995